BMRN vs RARE
BMRN: BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise. RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
Side-by-side fundamentals
| Metric | BMRN | RARE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.40 | $27.65 | |
| Market cap as of 2026-07-23 | $11.3B | $2.8B | |
| P/E as of 2026-07-23 | 42.00 | n/a | |
| PEG as of 2026-07-23 | n/a | -1.23 | |
| Net margin as of 2026-07-23 | +8.3% | -91.0% | BMRN higher |
| Gross margin as of 2026-07-23 | +80.2% | +83.6% | RARE higher |
| Operating margin as of 2026-07-23 | +9.7% | -83.8% | BMRN higher |
| ROE as of 2026-07-23 | +4.4% | -414.2% | BMRN higher |
| ROA as of 2026-07-23 | +3.4% | -45.7% | BMRN higher |
| Debt / equity as of 2026-07-23 | 0.23 | 90.54 | BMRN lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | +13.3% | RARE higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +22.8% | RARE higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.23 | 0.28 | |
| 1-year return as of 2026-07-22 close | -1.4% | +4.6% | RARE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.